Investigating CJC-1295 and Ipamorelin in Preclinical Models
CJC-1295 and Ipamorelin are two distinct peptides frequently studied together in research settings due to their complementary mechanisms involving growth hormone release pathways. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue. Researchers commonly investigate this combination for its synergistic effects on GH pulse amplitude and frequency in preclinical models.
Mechanisms of Action
CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, stimulating the release of growth hormone. Its DAC modification extends its half-life significantly compared to native GHRH. Ipamorelin acts on ghrelin receptors (GHS-R1a) and is noted in studies for its selectivity ā it does not significantly stimulate cortisol, prolactin, or ACTH release at research doses. Published research has examined this pairing in preclinical models investigating GH-axis signaling, body-composition endpoints, and recovery-physiology endpoints.
*For laboratory and research purposes only. Not for human or animal consumption.*
Disclaimer: The information provided in this article is for educational and informational purposes only. All compounds discussed are for laboratory and research purposes only. Not for human or animal consumption. No medical claims are made.
